Radiation oncology firm Accuray is highlighting data from a study that showed 98.4% of men with low-risk prostate cancer who underwent stereotactic body radiation therapy (SBRT) with the company's CyberKnife system had local disease control 10 years later.
The study was published online September 9 in Cureus. The researchers, led by Dr. Alan Katz of Flushing Radiation Oncology in New York City, studied 230 men with low-risk prostate cancer who completed their treatment in five daily sessions, compared with conventional radiation therapy, which can take 30 to 40 sessions. The men received treatment doses of 35 Gy each day.
In addition to the high rate of local disease control, Katz and colleagues also found a 93.7% disease-free survival rate, Accuray said.
